Acumen Pharmaceuticals, Inc.

ABOS

Explore Our Financial Data > Companies > Acumen Pharmaceuticals, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ABOS
CIK	0001576885
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	427 PARK ST., CHARLOTTESVILLE, VA, 22902
Website	acumenpharm.com
Phone	925-368-8508
CEO	Daniel J. OConnell
Employees	20

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-116.25 million
Net Income	$-116.25 million
Net Income to Common	$-116.25 million
EPS	$-1.94

View All

Balance Sheet

Cash	$30.16 million
Assets	$204.48 million
Liabilities	$48.96 million
Common Equity	$155.52 million
Liabilities & Equity	$204.48 million

View All

Cash Flow Statement

Net Income	$-116.25 million
Cash From Operating Activities	$-102.48 million
Cash From Investing Activities	$85.92 million
Cash From Financing Activities	$-215,000.00
Change in Cash	$-16.77 million

View All

Calculations

NOPAT	$-88.63 million
EBITDA	$-128.60 million
Price to Earnings	N/A
Price to Book	$0.51
ROE	-55.68%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITU

Article Link

Acumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

Acumen Pharmaceuticals Inc (ABOS) showcases rapid study enrollment and promising biomarker developments, despite reporting a net loss and facing competitive pressures in Alzheimer's research.

Article Link

Q1 2025 Acumen Pharmaceuticals Inc Earnings Call

Article Link

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” o

Article Link

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. The live webcasts may be accessed under the Investors tab on www.

Article Link